The novel PI3 kinase inhibitor, BAY 80-6946, impairs melanoma growth in vivo and in vitro

Experimental Dermatology

Volumn 23, Issue 8, 2014, Pages 579-584

  Schneider, Philine ^a   Schön, Margarete ^a   Pletz, Nadin ^a   Seitz, Cornelia S ^a   Liu, Ningshu ^b   Ziegelbauer, Karl ^b   Zachmann, Karolin ^a   Emmert, Steffen ^a   Schön, Michael P ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b BAYER PHARMA AG   (Germany)

Author keywords

Akt signaling; Chemotherapy; Melanoma; PI3Kinase

Indexed keywords

COPANLISIB; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE B; 2-AMINO-N-(7-METHOXY-8-(3-MORPHOLINOPROPOXY)-2,3-DIHYDROIMIDAZO(1,2-C)QUINAZOLIN-4-YL)PYRIMIDINE-5-CARBOXAMIDE; ENZYME INHIBITOR; PYRIMIDINE DERIVATIVE; QUINAZOLINE DERIVATIVE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER MODEL; CANCER PROGNOSIS; CANCER RESISTANCE; CELL CYCLE ARREST; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MELANOMA; MELANOMA CELL LINE; MOUSE; NONHUMAN; XENOTRANSPLANTATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CULTURE; CELL CYCLE; CELL PROLIFERATION; DRUG EFFECTS; DRUG SCREENING; METABOLISM; NUDE MOUSE; PATHOLOGY; PATHOPHYSIOLOGY; SIGNAL TRANSDUCTION; SKIN TUMOR; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CELLS, CULTURED; ENZYME INHIBITORS; HUMANS; IN VITRO TECHNIQUES; MELANOMA; MICE; MICE, NUDE; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PYRIMIDINES; QUINAZOLINES; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84905369078     PISSN: 09066705     EISSN: 16000625     Source Type: Journal    
DOI: 10.1111/exd.12470     Document Type: Article

References (44)

1. Hartsough E, Shao Y, Aplin A E. J Invest Dermatol 2014: 134: 319-325.
2. Lito P, Rosen N, Solit D B. Nat Med 2013: 19: 1401-1409.
3. Nakanishi C, Toi M. Nat Rev Cancer 2005: 5: 297-309.
4. Helmbach H, Rossmann E, Kern M A et al. Int J Cancer 2001: 93: 617-622.
5. Soengas M S, Lowe S W. Oncogene 2003: 22: 3138-3151.
6. Burgeiro A, Mollinedo F, Oliveira P J. Curr Cancer Drug Targets 2013: 13: 879-894.
7. Chapman P B, Hauschild A, Robert C et al. N Engl J Med 2011: 364: 2507-2516.
8. Hodi F S, O'Day S J, McDermott D F et al. N Engl J Med 2010: 363: 711-723.
9. Robert C, Thomas L, Bondarenko I et al. N Engl J Med 2011: 364: 2517-2526.
10. Sosman J A, Kim K B, Schuchter L et al. N Engl J Med 2012: 366: 707-714.
11. Grossman D, Altieri D C. Cancer Metastasis Rev 2001: 20: 3-11.
12. Grossman D, Kim P J, Schechner J S et al. Proc Natl Acad Sci USA 2001: 98: 635-640.
13. Lens M. Br J Nurs 2008: 17: 300-305.
14. Kim J E, Stones C, Joseph W R et al. BMC Cancer 2012: 12: 141.
15. Dai D L, Martinka M, Li G. J Clin Oncol 2005: 23: 1473-1482.
16. Dhawan P, Singh A B, Ellis D L et al. Cancer Res 2002: 62: 7335-7342.
17. Granville C A, Memmott R M, Gills J J et al. Clin Cancer Res 2006: 12: 679-689.
18. Krasilnikov M, Adler V, Fuchs S Y et al. Mol Carcinog 1999: 24: 64-69.
19. Liu N, Rowley B R, Bull C O et al. Mol Cancer Ther 2013: 12: 2319-2330.
20. Glauer J, Pletz N, Schön M et al. Blood Cancer J 2013: 3: e141.
21. Madhunapantula S V, Mosca P J, Robertson G P. Cancer Biol Ther 2011: 12: 1032-1049.
22. Pal I, Mandal M. Acta Pharmacol Sin 2012: 33: 1441-1458.
23. Engelman J A, Luo J, Cantley L C. Nat Rev Genet 2006: 7: 606-619.
24. Smalley K S. J Invest Dermatol 2010: 130: 28-37.
25. Dufourny B, van Teeffelen H A, Hamelers I H et al. J Endocrinol 2000: 166: 329-338.
26. Muise-Helmericks R C, Grimes H L, Bellacosa A et al. J Biol Chem 1998: 273: 29864-29872.
27. Jiang B H, Liu L Z. Adv Cancer Res 2009: 102: 19-65.
28. Sinnberg T, Sauer B, Holm P et al. Exp Dermatol 2012: 21: 265-270.
29. Birck A, Ahrenkiel V, Zeuthen J et al. J Invest Dermatol 2000: 114: 277-280.
30. Dankort D, Curley D P, Cartlidge R A et al. Nat Genet 2009: 41: 544-552.
31. Smalley K S, Haass N K, Brafford P A et al. Mol Cancer Ther 2006: 5: 1136-1144.
32. Becker J C, Schrama D, Bröcker E B et al. J Dtsch Dermatol Ges 2005: 3: 762-767.
33. Rebecca VW, Wood ER, Fedorenko IV et al. Mol Cell Proteomics 2014: e-pub ahead of print.
34. Kwong L N, Davies M A. Clin Cancer Res 2013: 19: 5310-5319.
35. Lassen A, Atefi M, Robert L et al. Mol Cancer Res 2014: 13: 83.
36. Davies M A. Cancer J 2012: 18: 142-147.
37. Vivanco I, Sawyers C L. Nat Rev Cancer 2002: 2: 489-501.
38. Aziz S A, Davies M, Pick E et al. Clin Cancer Res 2009: 15: 3029-3036.
39. Marone R, Erhart D, Mertz A C et al. Mol Cancer Res 2009: 7: 601-613.
40. Meier F, Busch S, Lasithiotakis K et al. Br J Dermatol 2007: 156: 1204-1213.
41. Bedogni B, O'Neill M S, Welford S M et al. Cancer Res 2004: 64: 2552-2560.
42. Shimizu T, Tolcher A W, Papadopoulos K P et al. Clin Cancer Res 2012: 18: 2316-2325.
43. Tran M A, Gowda R, Sharma A et al. Cancer Res 2008: 68: 7638-7649.
44. Pletz N, Schön M, Ziegelbauer K et al. Exp Dermatol 2012: 21: 301-304.